Buscar recursos académicos

Advanced prostate cancer (PCa) represents the fifth cause of cancer death worldwide. Although survival has improved with second-generation androgen signaling and Parp inhibitors, the benefits are not long-lasting, and ne...

Abstract The prognostic impact of age in bone-only metastatic prostate cancer (BoM-PCa) remains insufficiently characterized. This study evaluated the association between age and cancer-specific mortality (CSM) in a popu...

Background and Purpose: Anatomical variations during prostate radiotherapy can cause discrepancies between planned and delivered doses, which may become more pronounced in (ultra-)hypofractionated regimens. However, a st...

OBJECTIVE: Patients with malignancies may develop autoimmune and rheumatic manifestations as a result of generation of autoantibodies, paraneoplastic syndromes, direct invasion of joints and muscles by the tumour cells, ...

Abstract Accurate early detection of clinically significant prostate cancer is crucial for improving patient outcomes. However, traditional diagnostic methods such as Digital Rectal Exam and Prostate-Specific Antigen (PS...

Abstract Background Although [¹⁸F]PSMA-1007 enables sensitive detection in prostate cancer, heterogeneity in PSMA expression and variable physiologic uptake can limit performance, whereas [¹⁸F]FAPI-42, targeting fi...

ObjectiveHigh-risk localized prostate cancer is often associated with a higher risk of disease progression post-surgery. While radical prostatectomy (RP) is a cornerstone treatment, neoadjuvant chemohormonal therapy (CHT...

Lutetium-177 (177Lu)-prostate specific membrane antigen (PSMA)-617 is a small-molecule radioligand therapy (RLT) drug targeting PSMA. By selectively delivering the β－ radiation emitted by 177Lu to PSMA-positive prosta...

Abstract Prostate cancer (PCa) is a leading malignancy in men, particularly challenging in its advanced stages due to treatment resistance and immune evasion. MicroRNA-1290 (miR-1290) was identified to be implicated in t...

BackgroundMacrophage polarization plays a critical role in shaping the immunosuppressive tumor microenvironment (TME) of prostate cancer (PCa). Tumor-associated macrophages (TAMs), particularly those exhibiting immunoreg...

BackgroundProstate cancer is the sixth most common cause of cancer-related death in males globally and is often identified as a secondary malignancy. Early detection and appropriate management increase the patient’s li...

Abstract Recent studies highlight the role of uric acid in tumor development, but its impact on prostate cancer (PCa) remains underexplored. This study aimed to investigate how uric acid influences PCa prognosis by analy...

Objective: To explore the imaging biomarkers obtained from baseline multi-modality imaging PET/CT before metastasis-directed therapy (MDT), which could offer early response prediction before MDT treatment, optimizing pat...

Abstract Current therapies for prostate cancer are limited by toxicity and acquired resistance, motivating development of biocompatible nanotherapeutics. Here, Solanum nigrum L.-derived nanovesicles (SDNVs) were isolated...

Abstract Prostate cancer (PCa) is a heterogeneous and prevalent neoplasm, traditionally stratified by PSA and Gleason Score. However, these biomarkers have prognostic limitations, driving the search for new molecular mar...

Abstract First-line treatment options for patients with metastatic hormone-sensitive prostate cancer (HSPC) are divided into two groups: androgen receptor signaling inhibitor (ARSI)-based doublet therapy and triplet ther...

Abstract Background Prostate cancer (PCa) is a common malignant tumor in men, with a high incidence rate, posing a serious threat to human health and quality of life. Neddylation is a major post-translation modification,...

Purpose: To evaluate the impact of intra- and interfractional motion on dose distribution and clinical outcome in prostate magnetic resonance (MR)-guided adaptive radiotherapy. Methods: Seventy-six patients were treated ...

Abstract Accurate tumor targeting is vital in prostate cancer (PCa) radiotherapy for precise dose delivery and minimizing healthy tissue exposure. Currently, no artificial intelligence (AI) tool exists to predict setup d...

PURPOSE: To evaluate magnetic resonance imaging (MRI)-targeted biopsy (MRI-TB) performance in detecting clinically significant prostate cancer (csPCa) with a Prostate Imaging Reporting and Data System (PI-RADS) score of ...

Abstract Background Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those...

Abstract Prostate cancer continues to impose a significant health burden worldwide and in the United States, with rising incidence, persistent mortality rates, and disparities in both incidence and patient outcomes. Adva...

Bone metastasis is a frequent and incurable consequence of advanced prostate cancer (PC). This process originates through an interplay between disseminated tumor cells and heterogeneous bone resident cells in the metasta...

Abstract Prostate cancer (PCa) is one of the most common malignancies in men worldwide, yet early detection and accurate risk stratification remain challenging. MicroRNAs (miRNAs), key post-transcriptional regulators, ha...